← Russell 3000 cross-section

CTS CTS CORP

Trailing twelve months to 2026-03-31 · as filed 2026-04-29, not restated
Technology

Scale

Market cap
$1.6bn
Revenue TTM
$555m
Net income TTM
$69m
Free cash flow
$88m
Composite score
64.3
Sector rank
#1743

Valuation

P / E
23.7
EV / EBITDA
12.6
EV / sales
2.8
FCF yield
5.34%
Earnings yield vs 10-yr
-0.52pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
12.5%
EBITDA margin
22.2%
ROE
12.4%
ROIC
18.9%
Revenue growth
7.6%

Insider activity, last 90 days

Net open-market
$-8.48m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Trivedi became a member of the Board, effective July 6, 2026. Results of Operations: Second Quarter 2026 versus Second Quarter 2025 The following table highlights changes in significant components of the Unaudited Condensed Consolidated Statements of Earnings for the quarters ended June 30, 2026 and June 30, 2025: Net sales were $144,780 in the second quarter of 2026, an increase of $9,471, or 7.0%, from the second quarter of 2025. Net sales to the diversified end markets increased $10,894, or 14.6%. We achieved continued growth in the medical and industrial end markets, while the aerospace and defense end market declined primarily due to the timing of contract awards. …CTS CORP, 10-Q, period ended 2026-06-30, filed 2026-07-28

Read the full passage →